Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Immunotherapy combined with Chemotherapy in Resectable Thoracic Esophageal Squamous Cell Cancer (NICE) with multiple lymph-node stations metastasis: an exploring phase II study

Next Previous
Search
Trial Profile

Neoadjuvant Immunotherapy combined with Chemotherapy in Resectable Thoracic Esophageal Squamous Cell Cancer (NICE) with multiple lymph-node stations metastasis: an exploring phase II study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Cancer metastases; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms NICE study

    • Most Recent Events

    • 29 Feb 2024 Status changed from not yet recruiting to recruiting.
    • 29 Feb 2024 Results (n=60) assessing Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy published in the Journal of Thoracic and Cardiovascular Surgery
    • 08 Jun 2021 Interim results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top